Claims for Patent: 6,376,479

Summary for Patent: 6,376,479

Title:	Method for treating and preventing hyperparathyroidism
Abstract:	A method for reducing or preventing elevated blood parathyroid hormone level in a human being suffering from primary hyperparathyroidism, secondary hyperparathyroidism, or hyperparathyroidism secondary to end stage renal disease by administering a sufficient amount of 1.alpha.,24(S)-(OH).sub.2 vitamin D.sub.2.
Inventor(s):	Knutson; Joyce C (Madison, WI), Bishop; Charles W. (Madison, WI)
Assignee:	Bone Care International, Inc. (Middleton, WI)
Application Number:	09/501,093
Patent Claims:	1. A method for lowering or maintaining lowered serum parathyroid hormone in human patients suffering from hyperparathyroidism, comprising: administering to said patients an effective amount of 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 to lower and maintain lowered serum parathyroid hormone levels. 2. The method of claim 1 wherein the hyperparathyroidism is primary hyperparathyroidism. 3. The method of claim 1 wherein the hyperparathyroidism is secondary hyperparathyroidism. 4. The method of claim 1 wherein the hyperparathyroidism is secondary to end stage renal disease. 5. The method of claim I wherein the 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered orally. 6. The method of claim 5 wherein the 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered in a weekly dosage of about 1 .mu.g to about 300 .mu.g. 7. The method of claim 5 wherein the 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered in a weekly dosage of about 30 .mu.g to about 200 .mu.g. 8. The method of claim 1 wherein the 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is co-administered with a calcium phosphate binder. 9. The method of claim 1 wherein said 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered in combination with at least one agent characterized by said agent's ability to reduce loss of bone mass, or bone mineral content in patients. 10. The method of claim 9 wherein said agent is other vitamin D compounds, conjugated estrogens, sodium fluorides, biphosphonates, cobalamin, pertussin toxin or boron. 11. The method of claim 1, wherein the administration of 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is parenteral. 12. The method of claim 11 wherein said administration is by intravenous injection, nasopharyngeal or mucosal absorption, or transdermal absorption. 13. The method of claim 11 wherein the 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered in a weekly dosage of about 1 .mu.g to about 150 .mu.g. 14. The method of claim 11 wherein the 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered in a weekly dosage of about 30 .mu.g to about 100 .mu.g. 15. The method of claim 1 wherein the administration of 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is nonparenteral. 16. A method of treating a human to alleviate or prevent the pathological effects of hyperparathyroidism, wherein the method comprises orally administering to the human in need thereof 1.alpha.,24(S)-(OH).sub.2 -vitamin D.sub.2 in an amount sufficient to lower or maintain lowered serum parathyroid hormone levels in said human to thereby alleviate or prevent the effects. 17. The method of claim 16, wherein said serum parathyroid hormone levels are measured by blood serum level of parathyroid hormone over time after ingestion. 18. The method of claim 16 wherein the hyperparathyroidism is primary hyperparathyroidism. 19. The method of claim 16 wherein the hyperparathyroidism is secondary hyperparathyroidism. 20. The method of claim 16 wherein the hyperparathyroidism is hyperparathyroidism secondary to end stage renal disease. 21. A method for lowering or maintaining lowered serum parathyroid hormone in a human patient suffering from secondary hyperparathyroidism, comprising: administering to said patient an effective amount of 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 to lower and maintain lowered serum parathyroid hormone levels. 22. The method of claim 21 wherein the .alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered orally. 23. The method of claim 22 wherein the 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered in a weekly dosage of about 1 .mu.g to about 300 .mu.g. 24. The method of claim 21 wherein the 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered parenterally. 25. The method of claim 24 wherein the 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered in a weekly dosage of about 1 .mu.g to about 150 .mu.g.

Details for Patent 6,376,479

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2015-04-03